Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Financials
Key financial figures for Rhythm Pharmaceuticals, Inc. Common Stock (Q3 2026).
IMCIVREE net product revenue of $92.1M, up 29% from Q2 2026 and from $51.3M in Q3 2025, as the acquired hypothalamic obesity launch passed 700 patient start forms. Net product revenue from global IMCIVREE sales was $92.1M versus $51.3M in Q3 2025 and $71.3M in Q2 2026 (the release cites +29% sequentially); nine-month 2026 revenue was $223.5M versus $137.5M a year earlier. The release gives no analyst estimate. U.S. revenue was $67.5M (73% of product revenue), up $16.5M or 32% from Q2, driven mainly by acquired HO demand plus continued BBS growth; ex-U.S. revenue was $24.7M (27%), up $4.4M or 22% sequentially. Patients on reimbursed therapy globally rose 20% from Q2. On the outlook: For the year ending December 31, 2026, Rhythm anticipates approximately $360 million to $380 million in Non-GAAP Operating Expenses (GAAP R&D of approximately $165 million to $175 million and GAAP SG&A of approximately $195 million to $205 million, excluding stock-based compensation); the company expects cash, cash equivalents and short-term investments as of September 30, 2026 to fund planned operations for at least 24 months. Figures are for Q3 2026, as Rhythm Pharmaceuticals Inc. reported them.
- Revenue
- $92M
- Net Income
- -$41M
- EPS
- $-0.61
- Total Assets
- $443M
- Operating Cash Flow
- -$3M
Recent quarters
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| Q3 FY2026 | $92M | -$41M | -$0.61 | -42.63% | -$4M |
| Q2 FY2026 | $71M | -$49M | -$0.73 | -68.14% | -$53M |
| Q1 FY2026 | $60M | -$56M | -$0.83 | -87.11% | -$44M |
| Q4 FY2025 | $57M | -$48M | -$0.73 | -82.2% | -$26M |
| Q3 FY2025 | $51M | -$53M | -$0.82 | -102.64% | -$27M |
Recent fiscal years
| Period | Revenue | Net Income | EPS | Operating Margin | Free Cash Flow |
|---|---|---|---|---|---|
| FY2025 | $190M | -$197M | -$3.11 | -101.19% | -$117M |
| FY2024 | $130M | -$261M | -$4.34 | -204.04% | -$114M |
| FY2023 | $77M | -$185M | -$3.20 | -238.1% | -$136M |
Frequently asked questions
What was Rhythm Pharmaceuticals Inc.'s revenue last quarter?
Rhythm Pharmaceuticals Inc. reported revenue of $92.1 million for Q3 FY2026, up 79.6% from the same period a year earlier.
Is Rhythm Pharmaceuticals Inc. profitable?
Not in its most recent reported period. Rhythm Pharmaceuticals Inc. reported a net loss of $41.4 million for Q3 FY2026, a net margin of -44.9% on revenue.
How has Rhythm Pharmaceuticals Inc.'s margin trended?
Operating margin was -42.63% in Q3 FY2026, compared with -102.64% in the same period a year earlier. The quarter by quarter series is on the SentiSense financials page.
How much free cash flow did Rhythm Pharmaceuticals Inc. generate?
Rhythm Pharmaceuticals Inc. generated free cash flow of -$3.6 million in Q3 FY2026, after capital expenditure.
Full income statement, balance sheet and cash flow for Rhythm Pharmaceuticals, Inc. Common Stock on SentiSense, with up to forty quarters and twenty fiscal years of history.